Helomics | GenomeWeb


The company also intends to eventually offer the two additions, which expand the granularity of its live-cell analysis platform, for clinical use.

Helomics will provide its technology to the GENE Consortium, formed to support the UK's 100,000 Genomes Project.

Helomics' tumor profiling products and services, including ChemoFx, will be available to more than 700,000 Prime Health Services providers.

Formerly called Precision Therapeutics, the company recently received a $60 million investment and ushered in new management.

NEW YORK (GenomeWeb) – Precision Therapeutics today announced a $60 million investment and a new name, Helomics.

NEW YORK (GenomeWeb) – Med BioGene today announced that it is ready to initiate proceedings against its commercial partner Precision Therapeutics to enforce a C$1 million (US$920,000) milestone payment due to Med BioGene.

NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.

Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.

NEW YORK (GenomeWeb News) – Med BioGene today said that it and its commercial partner, Precision Therapeutics, have settled litigation with Signal Genetics and its Respira Health subsidiary, ending a dispute over an alleged breach of contract that began more than two years ago.

A prospective study slated for publication has demonstrated that Precision Therapeutics' ChemoFx test was able to predict whether ovarian cancer patients would live longer if they took a particular chemotherapy.


In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.